Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and COPD.

The collaboration will kick off with the development of a drug candidate for intermediate Phase II clinical trials, the British company said. Janssen, a unit of Johnson & Johnson, will then use Vectura’s dry powder inhaler technologies in the development of inhaled therapeutics for airways-related diseases such as asthma, Vectura said.